- Conditions
- Hypercholesterolemia
- Interventions
- MK-0616
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- South Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 7,607
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Cord Injuries
- Interventions
- 5HTP, L-DOPA, Placebo oral tablet, Carbidopa
- Drug
- Lead sponsor
- Jessica M D'Amico
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Pancreatitis, Acute
- Interventions
- Pirfenidone Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Rochester, Minnesota
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Obeticholic Acid, Atorvastatin, Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
- Conditions
- Diabetes Mellitus
- Interventions
- Pioglitazone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- RAD001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 23 Years to 76 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • New Orleans, Louisiana • Dallas, Texas + 1 more
- Conditions
- Overactive Bladder
- Interventions
- Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets, Placebo orally disintegrating tablets
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 24
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
- Interventions
- Entinostat
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Colorectal Neoplasms
- Interventions
- Vicriviroc, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
- Conditions
- Candidiasis, Vulvovaginal
- Interventions
- VT-1161, Fluconazole
- Drug
- Lead sponsor
- Viamet
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 8
- States / cities
- Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more
- Conditions
- Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Angeles, California + 15 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 29
- States / cities
- Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- U3-1287, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
- Conditions
- neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
- Interventions
- Sorafenib (Nexavar)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 9
- States / cities
- Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more
- Conditions
- Total Knee Arthroplasty
- Interventions
- Oxycodone, Placebo Oral Tablet
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Immune System Disorder, Healthy Volunteers
- Interventions
- Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Symptomatic Non-erosive Gastroesophageal Reflux Disease
- Interventions
- Vonoprazan, Placebo
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Mentor, Ohio
- Conditions
- Hepatitis B, Chronic
- Interventions
- Entecavir, Tenofovir, Adefovir, Lamivudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 58
- States / cities
- Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Chronic Iron Overload Due to Transfusion-dependant Anemias
- Interventions
- Deferasirox dispersible tablet, Defearisox film-coated tablet
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Hepatic Impairment
- Interventions
- S-217622
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Ibandronate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Female only
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 60
- States / cities
- Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more